Biopharmaceutical
Pharmaceutical
Health

AbbVie

38,973

$93.10
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.15 (+2.37%) Today
+$0.06 (+0.06%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell AbbVie and other stocks, options, ETFs, and crypto commission-free!

About ABBV

ABBVIE INC., also called AbbVie, is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. Read More The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

CEO
Richard A. Gonzalez
Employees
30,000
Headquarters
North Chicago, Illinois
Founded
2011
Market Cap
163.97B
Price-Earnings Ratio
16.11
Dividend Yield
5.18
Average Volume
10.99M
High Today
$93.48
Low Today
$90.25
Open Price
$90.34
Volume
9.53M
52 Week High
$97.86
52 Week Low
$62.55

Collections

Biopharmaceutical
Pharmaceutical
Health
Manufacturing
Cancer Prevention
Technology
2013 IPO
US

ABBV News

Yahoo FinanceJun 2

MARKETS: Dow surges into the close, up 268 points — YF Premium is bullish on Abbvie

Yahoo Finance's Jared Blikre joins Seana Smith to break down the day's price action in stocks as well as a long in Abbvie (ABBV), a Yahoo Finance Premium Invest
124
ReutersJun 1

BRIEF-Abbvie And Jacobio Announce Strategic Collaboration To Advance Shp2 Inhibitors

June 1 (Reuters) - Abbvie Inc: * ABBVIE AND JACOBIO ANNOUNCE STRATEGIC COLLABORATION TO ADVANCE SHP2 INHIBITORS * UNDER TERMS OF AGREEMENT, ABBVIE WILL BE GRA
1,004
ReutersMay 29

BRIEF-FDA Approves Abbvie's Oriahnn To Treat Heavy Menstrual Bleeding Associated With Fibroids In Women

May 29 (Reuters) - FDA: * FDA APPROVES NEW OPTION TO TREAT HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH FIBROIDS IN WOMEN * FDA - APPROVAL OF ORIAHNN GRANTED FOR
1,461

ABBV Earnings

$0.00
$0.81
$1.61
$2.42
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Estimated
— per share
Actual
Expected Jul 24, Pre-Market

You May Also Like

XYL
FNCB
NTR
PUB
WBIE
SMN
AWI
EXPR
USMV
XMPT

More ABBV News

ReutersMay 29

FDA approves Abbvie's drug to control menstrual bleeding due to fibroids

(Reuters) - The U.S. Food and Drug Administration on Friday approved Abbvie Inc’s oral treatment for managing heavy menstrual bleeding associated with fibroids
173
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.

Buy ABBV

Market Price$93.10
Commissions$0.00
Estimated Cost
$0.00
Sign up for a Robinhood Account to buy or sell AbbVie stock and options commission-free.
LearnBlogCareersHelpLog InSign Up